论文部分内容阅读
目前对放疗在甲状腺癌的治疗中的作用仍有争论,各家报告的结果不全相同,这是因为:(1)分化型甲状腺癌的生长速度很慢,需长期随访才能真正判定某一疗法的效果。如作者收集的548例分化型甲状腺癌中,74例存活20年以上,其中14例在初次治疗后22～34年因癌肿复发死亡。(2)手术后所谓的预防性放疗缺乏对照组比较,一般甲状腺癌对放射不敏感,放射量高达5,000 rad才能奏效,但各家报道的用量因不同手术内容而很不一致。(3)很多报告将预防性放射与切除不彻底和不能切除术后的放射病例不
At present, the role of radiotherapy in the treatment of thyroid cancer is still controversial, and the results reported by each are not identical. This is because: (1) The growth rate of differentiated thyroid cancer is very slow, and long-term follow-up is required to truly determine the treatment of a certain thyroid cancer. effect. Of the 548 patients with differentiated thyroid cancer collected by the authors, 74 survived for more than 20 years, and 14 of them died of cancer recurrence 22 to 34 years after the initial treatment. (2) After the surgery, the so-called preventive radiotherapy lacks the comparison of the control group. In general, thyroid cancer is insensitive to radiation and the radiation dose is as high as 5,000 rad. However, the reported doses vary according to different surgical contents. (3) Many reports do not include preventive radiation and incomplete resection and radiotherapy after resection.